Retreatment with peginterferon and ribavirin in chronic hepatitis C

World Journal of Gastroenterology

Volumn 21, Issue 6, 2015, Pages 1994-1999

  Jo, Yong Min ^a   Lee, Sung Wook ^a   Han, Sang Young ^a   Baek, Yang Hyun ^a   Kim, Soo Young ^a   Kim, Woo Jae ^a   Ahn, Ji Hye ^a   Lee, Ji Young ^a  

^a Dong A University   (South Korea)

Author keywords

Chronic hepatitis C; Direct acting antiviral agents; Peginterferon; Retreatment; Ribavirin

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; ECHOGRAPHY; GENOTYPE; HEPATITIS C; HUMAN; INFORMED CONSENT; INTRAVENOUS DRUG ABUSE; LEUKOPENIA; LIVER FUNCTION; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PROTHROMBIN TIME; RETREATMENT; RETROSPECTIVE STUDY; SEXUAL INTERCOURSE; SPLENOMEGALY; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; RECURRENT DISEASE; TIME FACTOR; TRANSMISSION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84922714085     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i6.1994     Document Type: Article

References (23)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]
2. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526 [PMID: 16941687 DOI: 10.1002/hep.21347]
3. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]
4. Shin HR. Epidemiology of hepatitis C virus in Korea. Intervirology 2006; 49: 18-22 [PMID: 16166784 DOI: 10.1159/000087258]
5. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46 [PMID: 12407575 DOI: 10.1002/hep.1840360706]
6. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562 [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107]
7. Holmes J, Thompson A, Bell S. Hepatitis C - an update. Aust Fam Physician 2013; 42: 452-456 [PMID: 23826595]
8. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-412 [PMID: 23199500 DOI: 10.1016/j.bpg.2012.09.009]
9. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359 [PMID: 16905701 DOI: 10.1136/gut.2005.076646]
10. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114-S120 [PMID: 12407584 DOI: 10.1002/hep.1840360715]
11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]
12. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171 [PMID: 15057920 DOI: 10.1002/hep.20119]
13. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/nejmoa1010494]
14. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/nejmoa1012912]
15. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
16. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
17. Victrelis (boceprevir; package insert). Whitehouse Station, NJ: Schering Corporation, 2011
18. Incivek (telaprevir; package insert). Cambridge, MA: Vertex Pharmaceuticals Inc, 2011
19. Susser S, Forestier N, Welker M, Vermehren J, Karey U, Zeuzem S, Sarrazin C. 12 Detection of resistant variants in the hepatitis C virus NS3 protease gene by clonal sequencing at long-term follow-up in patients treated with boceprevir. Hepatology 2009; 50: S7 [DOI: 10.1016/S0168-8278(09)60014-3]
20. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777 [PMID: 17484874 DOI: 10.1053/j.gastro.2007.02.037]
21. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850 [PMID: 19403903 DOI: 10.1056/nejmoa0807650]
22. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/nejmoa020047]
23. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652 [PMID: 12939591 DOI: 10.1053/jhep.2003.50364]